|
|
| | LXH254,LXH-254 Basic information |
| Product Name: | LXH254,LXH-254 | | Synonyms: | LXH254; LXH-254; LXH 254;LXH254,LXH-254;LXH254;4-Pyridinecarboxamide, N-[3-[2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl]-4-methylphenyl]-2-(trifluoromethyl)-;Naporafenib;Bcr-Abl,A375,Inhibitor,p38 MAPK,LXH 254,inhibit,Raf,Mia PaCa-2,Raf kinases,HCT116,LXH254,Selective,MEL-JUSO,LXH-254;N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide;Naporafenib (LXH-254) | | CAS: | 1800398-38-2 | | MF: | C25H25F3N4O4 | | MW: | 502.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1800398-38-2.mol |  |
| | LXH254,LXH-254 Chemical Properties |
| Boiling point | 601.9±55.0 °C(Predicted) | | density | 1.353±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:100.0(Max Conc. mg/mL);199.0(Max Conc. mM) | | form | A crystalline solid | | pka | 10.86±0.70(Predicted) | | color | Off-white to light yellow |
| | LXH254,LXH-254 Usage And Synthesis |
| Uses | LXH254, is a kinase inhibitor used in the treatment of solid tumors. |
| | LXH254,LXH-254 Preparation Products And Raw materials |
|